Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mevrometostat - Pfizer

Next Previous
Drug Profile

Mevrometostat - Pfizer

Alternative Names: PF-06821497

Latest Information Update: 24 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Isoquinolines; Pyridines; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer
  • Phase I Follicular lymphoma; Small cell lung cancer

Most Recent Events

  • 19 Jun 2025 Pfizer plans a phase III trial for Prostate cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA, China, Japan (PO) in August 2025 (NCT07028853)
  • 11 Nov 2024 Pfizer completes a phase I trial (In volunteers) in Netherlands (PO, Suspension) (NCT06392230)
  • 24 Oct 2024 Pfizer plans a phase I bioavailability trial(PO, Tablet) in December 2024 (NCT06661694)(EudraCT2024-516907-18-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top